Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
December 01, 2017

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Q2 Solutions vaccine lab services play major part in establishing efficacy in trial for influenza vaccine development
Improved influenza vaccines are needed to control seasonal epidemics. This New England Journal of Medicine article highlights an Influenza vaccine development trial that compares the protective efficacy in older adults of a quadrivalent, recombinant influenza vaccine (RIV4) with a standard-dose, egg-grown, quadrivalent, inactivated influenza vaccine (IIV4) during the A/H3N2-predominant 2014–2015 influenza season, when antigenic mismatch between circulating and vaccine influenza strains resulted in the reduced effectiveness of many licensed vaccines.

Download this article to explore the methods and conclusions of this clinical trial, where Q2 Solutions' (formerly Focus Diagnostics) vaccine lab played a major role in establishing efficacy for this vaccine to be licensed for use.

Related Services:
Keeping Up with the Flu: Advances in seasonal influenza vaccine development

Q2 Solutions Anti-infective and Vaccine Development Services

Assays to drive success in anti-infective and vaccine development

Extensive expertise for vaccine assay development and diagnostics

Zika Vaccine Research: Complex Steps Toward a Critical Need

Overcoming Zika vaccine development challenges

Read More